Chordate Medical Holding AB (publ) (CMH.ST)
SEK 12.6
(-1.18%)
SEK 12.6
(-1.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -27.94 Million SEK | -6.28% |
| 2022 | -26.78 Million SEK | -26.59% |
| 2021 | -20.5 Million SEK | -19.87% |
| 2020 | -18.05 Million SEK | 11.0% |
| 2019 | -22.53 Million SEK | -2.01% |
| 2018 | -18.15 Million SEK | -22.1% |
| 2017 | -15.2 Million SEK | -123.33% |
| 2016 | -9.04 Million SEK | 27.33% |
| 2015 | -9.48 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.46 Million SEK | 40.65% |
| 2024 Q2 | -6.57 Million SEK | -20.1% |
| 2023 Q4 | -9.39 Million SEK | -109.39% |
| 2023 Q1 | -6.49 Million SEK | 17.2% |
| 2023 Q3 | -4.48 Million SEK | 33.42% |
| 2023 Q2 | -6.73 Million SEK | -3.72% |
| 2023 FY | - SEK | -6.28% |
| 2022 Q1 | -6.77 Million SEK | -3.37% |
| 2022 FY | - SEK | -26.59% |
| 2022 Q4 | -7.84 Million SEK | -41.1% |
| 2022 Q3 | -5.56 Million SEK | -3.23% |
| 2022 Q2 | -5.38 Million SEK | 20.48% |
| 2021 FY | - SEK | -19.87% |
| 2021 Q1 | -5.48 Million SEK | -4.54% |
| 2021 Q2 | -4.74 Million SEK | 13.52% |
| 2021 Q3 | -3.41 Million SEK | 28.17% |
| 2021 Q4 | -6.55 Million SEK | -92.19% |
| 2020 Q1 | -4.15 Million SEK | 9.64% |
| 2020 Q4 | -5.25 Million SEK | -40.79% |
| 2020 FY | - SEK | 11.0% |
| 2020 Q3 | -3.72 Million SEK | -0.22% |
| 2020 Q2 | -3.72 Million SEK | 10.37% |
| 2019 FY | - SEK | -2.01% |
| 2019 Q1 | -4.42 Million SEK | 8.58% |
| 2019 Q2 | -4.78 Million SEK | -8.12% |
| 2019 Q3 | -5.13 Million SEK | -7.21% |
| 2019 Q4 | -4.59 Million SEK | 10.44% |
| 2018 Q3 | -4.16 Million SEK | 5.94% |
| 2018 FY | - SEK | -22.1% |
| 2018 Q2 | -4.42 Million SEK | 6.36% |
| 2018 Q1 | -4.72 Million SEK | 12.31% |
| 2018 Q4 | -4.84 Million SEK | -16.33% |
| 2017 Q1 | -2.39 Million SEK | -207.07% |
| 2017 FY | - SEK | -123.33% |
| 2017 Q2 | -3.43 Million SEK | -43.6% |
| 2017 Q3 | -3.98 Million SEK | -15.76% |
| 2017 Q4 | -5.38 Million SEK | -35.38% |
| 2016 Q3 | -1.86 Million SEK | 32.52% |
| 2016 Q2 | -2.76 Million SEK | 0.0% |
| 2016 FY | - SEK | 27.33% |
| 2016 Q4 | 2.23 Million SEK | 219.82% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 63.768% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 106.784% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 106.784% |
| Arcoma AB | 6.24 Million SEK | 547.231% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 68.946% |
| BICO Group AB (publ) | 322.3 Million SEK | 108.67% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 142.351% |
| CellaVision AB (publ) | 207.24 Million SEK | 113.483% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 59.151% |
| C-Rad AB (publ) | 48.9 Million SEK | 157.138% |
| Duearity AB (publ) | -24.77 Million SEK | -12.769% |
| Dignitana AB (publ) | -264 Thousand SEK | -10484.469% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 68.138% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.471% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 58.449% |
| Iconovo AB (publ) | -35.33 Million SEK | 20.921% |
| Integrum AB (publ) | 8.76 Million SEK | 418.928% |
| Luxbright AB (publ) | -23.86 Million SEK | -17.079% |
| Mentice AB (publ) | 28.87 Million SEK | 196.779% |
| OssDsign AB (publ) | -122.02 Million SEK | 77.1% |
| Paxman AB (publ) | 31.22 Million SEK | 189.478% |
| Promimic AB (publ) | -3.68 Million SEK | -658.496% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 81.434% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 46.086% |
| ScandiDos AB (publ) | -13.35 Million SEK | -109.217% |
| Sectra AB (publ) | 615.06 Million SEK | 104.543% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 45.924% |
| Senzime AB (publ) | -118.82 Million SEK | 76.484% |
| SpectraCure AB (publ) | -20.96 Million SEK | -33.259% |
| Stille AB | 56.04 Million SEK | 149.862% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.123% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 122.076% |